[Skip to Content]
[Skip to Content Landing]
November 27, 1972

Combination Therapy of Acute Lymphocytic Leukemia of Children

Author Affiliations

From the Cancer Clinical Research Center, Roswell Park Memorial Institute, Buffalo.

JAMA. 1972;222(9):1169-1170. doi:10.1001/jama.1972.03210090049022

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


Successive studies in the combination chemotherapy of acute lymphocytic leukemia of children, conducted by the Acute Leukemia Group B, have been characterized by increasing survival. In 1956, no child among the 39 studied lived 2 years. In 1966, 27% have survived five years, and programs of chemotherapy begun in 1968 and in 1971 by life-table technique project to even greater survival prediction. Each study program contains multiple regimens of chemotherapy. In the best regimen studied in 1966, intensive chemotherapy with eight months of repeated courses of methotrexate after vincristine-prednisone induction, with vincristine-prednisone reinforcement of the methotrexate treatment, singled out nine children of the 55 who still are alive and well without evidence of disease four years or more after completion of the last drug treatment. These children respond entirely differently from the other 46 children, each of whom relapsed within two years. Thus, the nine children have a good possibility